Please login to the form below

Not currently logged in
Email:
Password:

aflibercep

This page shows the latest aflibercep news and features for those working in and with pharma, biotech and healthcare.

NICE first fast-track appraisal backs Bayer's Eylea

NICE first fast-track appraisal backs Bayer's Eylea

The National Institute for Health and Care Excellence (NICE) has issued its first fast-track guidance, recommending Bayer’s Eylea (aflibercep) in choroidal neovascularisation (CNV).

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics